Systematic Screening of Chemokines to Identify Candidates to Model and Create Ectopic Lymph Node Structures for Cancer Immunotherapy

The induction of ectopic lymph node structures (ELNs) holds great promise to augment immunotherapy against multiple cancers including metastatic melanoma, in which ELN formation has been associated with a unique immune-related gene expression signature composed of distinct chemokines. To investigate the therapeutic potential of ELNs induction, preclinical models of ELNs are needed for interrogation of these chemokines. Computational models provide a non-invasive, cost-effective method to investigate leukocyte trafficking in the tumor microenvironment, but parameterizing such models is difficult due to differing assay conditions and contexts among the literature. To better achieve this, we systematically performed microchemotaxis assays on purified immune subsets including human pan-T cells, CD4+ T cells, CD8+ T cells, B cells, and NK cells, with 49 recombinant chemokines using a singular technique, and standardized conditions resulting in a dataset representing 238 assays. We then outline a groundwork computational model that can simulate cellular migration in the tumor microenvironment in response to a chemoattractant gradient created from stromal, lymphoid, or antigen presenting cell interactions. The resulting model can then be parameterized with standardized data, such as the dataset presented here, and demonstrates how a computational approach can help elucidate developing ELNs and their impact on tumor progression.

[1]  E. Tartour,et al.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[3]  Edwin Wang,et al.  Cancer systems biology in the genome sequencing era: part 1, dissecting and modeling of tumor clones and their networks. , 2013, Seminars in cancer biology.

[4]  M. Berwick,et al.  Predicting five‐year outcome for patients with cutaneous melanoma in a population‐based study , 1996, Cancer.

[5]  Jeffrey E. Lee,et al.  Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients , 2012, Clinical Cancer Research.

[6]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[7]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[8]  J. Mulé,et al.  Cancer immunotherapy meets biomaterials , 2015, Nature Biotechnology.

[9]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[10]  T. Hara,et al.  Lymph Node Fibroblastic Reticular Cells Construct the Stromal Reticulum via Contact with Lymphocytes , 2004, The Journal of experimental medicine.

[11]  P. Sparén,et al.  Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. , 1994, Journal of the National Cancer Institute.

[12]  J. Mulé,et al.  Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes , 2017, Breast Cancer Research.

[13]  T. Yeatman,et al.  Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. , 2011, The American journal of pathology.

[14]  S. Rosenberg,et al.  In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. , 1989, Journal of the National Cancer Institute.

[15]  Greta M. Massetti,et al.  Vital Signs: Melanoma Incidence and Mortality Trends and Projections — United States, 1982–2030 , 2015, MMWR. Morbidity and mortality weekly report.

[16]  Natale Cascinelli,et al.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.

[17]  L. C. Bidwell,et al.  Effects of Maternal Smoking during Pregnancy on Offspring Externalizing Problems: Contextual Effects in a Sample of Female Twins , 2016, Behavior genetics.

[18]  Edwin Wang,et al.  Cancer systems biology in the genome sequencing era: part 2, evolutionary dynamics of tumor clonal networks and drug resistance. , 2013, Seminars in cancer biology.

[19]  W. Paul,et al.  Differentiation of Effector CD 4 T Cell Populations ∗ , 2014 .

[20]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[21]  T. Larsen,et al.  A RETROSPECTIVE HISTOLOGICAL STUDY OF 669 CASES OF PRIMARY CUTANEOUS MALIGNANT MELANOMA IN CLINICAL STAGE I , 1979, Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology.

[22]  M. Donia,et al.  Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients , 2012, Journal of Translational Medicine.

[23]  Ying Xu,et al.  Lymphocyte Sequestration Through S1P Lyase Inhibition and Disruption of S1P Gradients , 2005, Science.

[24]  C. Slingluff,et al.  Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. , 2012, Cancer research.

[25]  Simon A. Jones,et al.  Ectopic lymphoid-like structures in infection, cancer and autoimmunity , 2014, Nature Reviews Immunology.

[26]  Mark J. Miller,et al.  Two-Photon Imaging of Lymphocyte Motility and Antigen Response in Intact Lymph Node , 2002, Science.

[27]  F. Marincola,et al.  A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma , 2002, Journal of immunotherapy.

[28]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[29]  J. Weber,et al.  Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential , 2015, Therapeutic advances in medical oncology.

[30]  S. Narumiya,et al.  The Chemokine Receptor CCR7 Activates in Dendritic Cells Two Signaling Modules That Independently Regulate Chemotaxis and Migratory Speed1 , 2005, The Journal of Immunology.

[31]  A. Balar,et al.  PD-1 and PD-L1 antibodies in cancer: current status and future directions , 2017, Cancer Immunology, Immunotherapy.

[32]  B. Shalmon,et al.  Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients , 2010, Clinical Cancer Research.

[33]  K. Søndergaard,et al.  Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases , 1985, Virchows Archiv A.

[34]  W. Paul,et al.  Differentiation of effector CD4 T cell populations (*). , 2010, Annual review of immunology.

[35]  J. Kirklin,et al.  Metastatic mediastinal neoplasm masquerading as aortic dissection: a skip sign on computed tomography for their distinction. , 1985, The Journal of computed tomography.

[36]  Pierre Validire,et al.  Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. , 2014, Cancer research.

[37]  H. Rosen,et al.  Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists , 2002, Science.

[38]  K. Rajewsky,et al.  Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma , 2015, Nature Immunology.

[39]  S. Friberg,et al.  On the growth rates of human malignant tumors: Implications for medical decision making , 1997, Journal of surgical oncology.

[40]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[41]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[42]  V. Sondak,et al.  12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy? , 2012, Scientific Reports.

[43]  A. Halpern,et al.  Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.

[44]  V. Sondak,et al.  Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma , 2012, Journal of immunotherapy.

[45]  Stuart Moss,et al.  Current Status and Future Directions , 2013 .

[46]  J. Wolchok,et al.  Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  Mark J. Miller,et al.  Autonomous T cell trafficking examined in vivo with intravital two-photon microscopy , 2003, Proceedings of the National Academy of Sciences of the United States of America.